Incyte (INCY) Expected to Announce Earnings on Tuesday

Incyte (NASDAQ:INCY) is expected to be announcing its Q4 2025 results before the market opens on Tuesday, February 10th. Analysts expect Incyte to post earnings of $1.96 per share and revenue of $1.3543 billion for the quarter. Parties may review the information on the company’s upcoming Q4 2025 earning report for the latest details on the call scheduled for Tuesday, February 10, 2026 at 8:00 AM ET.

Incyte Stock Performance

Shares of INCY stock opened at $108.39 on Friday. The company has a current ratio of 3.20, a quick ratio of 3.13 and a debt-to-equity ratio of 0.01. The company has a market cap of $21.28 billion, a PE ratio of 18.16, a P/E/G ratio of 0.65 and a beta of 0.82. The company’s fifty day simple moving average is $101.69 and its 200-day simple moving average is $93.14. Incyte has a 52 week low of $53.56 and a 52 week high of $112.29.

Analyst Ratings Changes

A number of research analysts have commented on INCY shares. Mizuho set a $121.00 price objective on Incyte and gave the stock an “outperform” rating in a research note on Monday, December 8th. Zacks Research lowered Incyte from a “strong-buy” rating to a “hold” rating in a research report on Monday, November 10th. Stifel Nicolaus set a $119.00 price target on Incyte in a report on Monday, January 5th. TD Cowen reiterated a “buy” rating on shares of Incyte in a research note on Tuesday, January 13th. Finally, Wall Street Zen raised shares of Incyte from a “buy” rating to a “strong-buy” rating in a research report on Saturday, November 1st. Nine investment analysts have rated the stock with a Buy rating, twelve have given a Hold rating and one has issued a Sell rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Hold” and an average target price of $103.29.

Insider Activity at Incyte

In other Incyte news, EVP Michael James Morrissey sold 54,008 shares of the firm’s stock in a transaction on Tuesday, December 16th. The shares were sold at an average price of $97.29, for a total transaction of $5,254,438.32. Following the completion of the transaction, the executive vice president directly owned 31,830 shares of the company’s stock, valued at $3,096,740.70. This trade represents a 62.92% decrease in their position. The sale was disclosed in a legal filing with the Securities & Exchange Commission, which is available at the SEC website. Also, insider Thomas Tray sold 2,774 shares of the company’s stock in a transaction dated Friday, December 19th. The shares were sold at an average price of $100.00, for a total transaction of $277,400.00. Following the completion of the sale, the insider owned 22,973 shares in the company, valued at approximately $2,297,300. This trade represents a 10.77% decrease in their position. Additional details regarding this sale are available in the official SEC disclosure. Over the last quarter, insiders have sold 95,225 shares of company stock valued at $9,519,745. 17.80% of the stock is owned by insiders.

Institutional Investors Weigh In On Incyte

A number of institutional investors have recently modified their holdings of the business. NewEdge Advisors LLC lifted its holdings in Incyte by 369.3% in the first quarter. NewEdge Advisors LLC now owns 12,597 shares of the biopharmaceutical company’s stock worth $763,000 after acquiring an additional 9,913 shares during the last quarter. Jones Financial Companies Lllp raised its position in shares of Incyte by 15.1% during the 1st quarter. Jones Financial Companies Lllp now owns 4,944 shares of the biopharmaceutical company’s stock worth $299,000 after purchasing an additional 648 shares during the period. Goldman Sachs Group Inc. lifted its holdings in shares of Incyte by 6.4% in the 1st quarter. Goldman Sachs Group Inc. now owns 814,559 shares of the biopharmaceutical company’s stock worth $49,322,000 after purchasing an additional 48,751 shares during the last quarter. United Services Automobile Association bought a new stake in shares of Incyte in the 1st quarter worth approximately $219,000. Finally, Focus Partners Wealth boosted its position in Incyte by 74.1% during the 1st quarter. Focus Partners Wealth now owns 21,024 shares of the biopharmaceutical company’s stock valued at $1,273,000 after purchasing an additional 8,951 shares during the period. Institutional investors own 96.97% of the company’s stock.

Incyte Company Profile

Incyte Corporation is a Wilmington, Delaware–based biopharmaceutical company focused on the discovery, development and commercialization of novel therapies in oncology and inflammation. Since its founding in 2002, Incyte has grown from a small research organization into a global enterprise, advancing a portfolio of internally developed and partnered assets. The company’s research and development efforts center on small-molecule drugs and biologics that modulate critical signaling pathways implicated in cancer, autoimmune disorders and rare diseases.

The company’s flagship product is Jakafi® (ruxolitinib), a Janus kinase (JAK) inhibitor approved for the treatment of myelofibrosis and polycythemia vera.